74
Flexible Pipetting Solutions for the Post-Pandemic Era
During the COVID-19 pandemic, Integra Biosciences pipetting solutions were widely purchased by laboratories to manage the high volume of samples received daily for PCR testing. As the pandemic situation has improved, labs can now focus on other important work. However, the question remains: what happened to the pipetting platforms and devices? Integra conducted a recent survey to shed light on how these systems are being repurposed now that they are no longer necessary for COVID-19 testing.
To streamline and expedite their PCR workflows during the pandemic, laboratories utilised various Integra pipetting systems such as VOYAGER adjustable tip spacing pipettes, VIAFLO lightweight electronic pipettes, VIAFLO 96 and VIAFLO 384 handheld electronic pipettes, MINI 96 portable electronic pipettes, and ASSIST PLUS pipetting robots. The instruments’ ease of use, intuitive operation, and uncomplicated programming facilitated automation. Currently, these same qualities are allowing the pipetting systems to be employed in various non-COVID applications, such as DNA sequencing, investigating antibiotic resistance, women’s health testing, and creating novel assays for prevalent diseases like STIs and monkeypox.
According to the survey, 75% of the labs opted for the ASSIST PLUS pipetting robot. The main reason for their preference was the robot’s capacity to automate multichannel pipettes, providing increased flexibility. Moreover, with the launch of the D-ONE single-channel pipetting module, the platform can now execute tasks that require a single channel. This feature allows the robot to accomplish time-consuming duties such as serial dilutions, sample normalisation, hit picking, and pipetting of intricate plate layouts with minimal manual intervention.
The survey highlighted that the primary advantage of utilising the ASSIST PLUS and the VOYAGER pipetting systems for automation was their ability to minimise errors, resulting in greater consistency, accuracy, and reproducibility of results. Furthermore, automating laborious and time- consuming liquid transfer steps translated into requiring fewer staff to handle more samples, ultimately improving lab throughput. Based on these positive experiences, 92% of customers intend to use their pipetting robots for additional applications in the future, such as allergy and infectious disease testing, pharmacogenomics, targeted genome sequencing, and research into antimicrobial resistance. By doing so, they can enhance their workflows and ensure adaptability to future diagnostic requirements.
More information online:
ilmt.co/PL/VobY 60116pr@reply-direct.com
Accelerating Assay Development with Lyophilisation-Optimised qPCR Reagents
Applied Biosystems has released the TaqMan™ 2.5X Lyo-Ready 1-step qPCR Master Mix with excipient, a ready-to-use formulation that can be easily incorporated into lyophilisation processes. This reagent undergoes functional testing for lot-to- lot reproducibility and is manufactured in an ISO 13485-certified facility to maintain high quality standards. The product also includes lyophilisation guidelines to facilitate a fast and reliable transition from liquid to lyophilised form.
Newcomers to lyophilisation may face difficulties in finding a suitable excipient and protocol for their qPCR-based assays. However, the TaqMan™ Lyo-Ready Master Mixes offer optimised performance both before and after lyophilisation, and come with guidelines to support molecular diagnostic kit manufacturers. This can help to shorten the path to commercialisation.
“The lyophilisation phase can be a challenging part of any workflow to navigate, even for those with experience,” said Kathy Latham, Senior Director, qPCR Reagents at Thermo Fisher Scientific. “Our Lyo-Ready Master Mixes take the guess work out of choosing an excipient and provide consistent performance. Taken together, we believe this will help our customers shorten the path from an idea to a commercial lyophilised product.”
The Lyo-Ready Master Mixes offer a fast and simplified workflow, reducing the time and cost required to develop robust lyophilisation protocols by 50%. These mixes are optimised to ensure consistent and reliable performance both before and after lyophilisation, offering precision performance. They are also tolerant to challenging conditions and are compatible with purified samples and crude lysates commonly found in biopharmaceutical, molecular diagnostic, and research applications.
More information online:
ilmt.co/PL/Gbnj 59871pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
